4.8 • 1.4K Ratings
🗓️ 24 November 2025
⏱️ 65 minutes
🧾️ Download transcript
Click on a timestamp to play from that location
| 0:00.0 | Behind the Knife listeners. |
| 0:25.1 | I'm welcoming back the colorepto oncology surgery team, including myself, Winnie Zambre, |
| 0:31.2 | Phil Bauer, and Dr. J. Joshua Smith. |
| 0:34.7 | Today, we have an outstanding panel of guests joining us. Dr. Garcia Aguilar, |
| 0:40.6 | who is the Beno C. Schmidt Chair in Surgical Encology, the chief of colorectal service in the |
| 0:46.8 | Department of Surgery at MSK, the director of Polorectal Cancer Research Center at MSK, and the professor of surgery at Wild Pernil Medical College. We also have Dr. Benjamin Schlector, senior physician and the gastrointestinal cancer center at the Dana Farber Cancer Institute, Assistant Professor of Medicine at Harvard Medical School. |
| 1:14.7 | Also joining us, we have Dr. Emmanuel Focas, professor and chairman at the Department of Radiation Oncology, |
| 1:23.7 | for the Cyberknife and Radiotherapy Faculty of Medicine Medicine at the University Hospital of Cologne in Germany. |
| 1:32.3 | We appreciate you all taking the time to discuss our topic today, total new adjuvant therapy and locally advanced rectal cancer. |
| 1:41.3 | Winnie, can you please provide us some background? Of course, Janet, locally advanced rectal cancer. Winnie, can you please provide us some background? |
| 1:45.8 | Of course, Janet. |
| 1:46.9 | Locally advanced rectal cancer includes CT3, that is, tumor invading through the |
| 1:52.1 | muscularis propria into the subcerosa and CT4 tumors, that is tumors that has penetrated |
| 1:58.1 | the outer layers or cirrhosa invading at adjacent organs or structures, |
| 2:03.1 | or tumors involving local regional lymph nodes in addition to any T-stage with node-positive |
| 2:09.3 | disease. It should be noted that CT3N-0-M-0 tumors also fall into this category. |
| 2:17.6 | NCCN guidelines recommend TOL NEAadrine therapy as a current standard of care for all non-metastatic |
| 2:22.8 | locally advanced disease, but this very slightly from European recommendations. |
| 2:27.9 | According to ESMO guidelines, T&T should be considered for high-risk tumors in the surgical |
| 2:32.8 | setting. |
| 2:33.8 | These are defined as |
| 2:34.7 | clinical T4 tumors, those with concern for mesorectal fashion involvement, clinical node N2 tumors, |
... |
Transcript will be available on the free plan in 3 days. Upgrade to see the full transcript now.
Disclaimer: The podcast and artwork embedded on this page are from Behind The Knife: The Surgery Podcast, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of Behind The Knife: The Surgery Podcast and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2025.